An interventional study of Multimodal intervention to Reduce Unwanted Loneliness in Family Caregivers of People With Alzheimer in Alzheimer Disease (AD), Unwanted Loneliness and Family Caregivers, sponsored by University of Valencia. Not yet recruiting at 1 site in Spain. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-06-15.
Sponsored by University of Valencia · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 279 studies in Alzheimer Disease with a site in Spain — 54 open to participants now, 80 under way, 24 of them phase 3. Alzheimer Disease · Spain.
Among the 279 studies in Alzheimer Disease with a site in Spain, this one is the 208th largest by planned enrollment of the 240 interventional ones that give a count, is one of 19 that started in 2026, is one of 66 with no phase, reaches primary completion later than 24 of the 79 other live ones, and was the 273rd registered.
3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →54 of the 279 studies in Alzheimer Disease with a site in Spain are open now. Recruiting first, the newest first:
Barcelonabeta Brain Research Center, Pasqual Maragall Foundation · Sites in Spain
Ages 55–85
Sanofi · Sites in Spain, United States, Australia and 4 more countries
Ages 55–85
Eidos Therapeutics, a BridgeBio company · Sites in Spain, United States, Singapore
Ages 18–80
Stichting International Registry for Alzheimer's Disease and other Dementias Foundation · Sites in Spain, Australia, Austria and 14 more countries
Ages 18+
Exciva GmbH · Sites in Spain, United States, Canada and 6 more countries
Ages 55–90
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
279 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 81 · Phase 3 94 · Phase 4 4
First in 2002; this study’s year is marked. 19 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Median enrollment 258 across the 240 interventional studies, 400 across the 39 observational. Of the 187 that completed or were terminated, 91 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
178 of 279 have an industry lead sponsor. The 10 most frequent:
University of Valencia is the lead sponsor of 357 studies on the registry; 75 are open to participants now.
University of Valencia has 5 studies filed under Alzheimer Disease — fewer than ten, so there is no comparison to draw.
20 of the studies in Alzheimer Disease with a site in Spain that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06585787Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | 2026-11-24 |
| NCT03887455Phase 3Eisai Inc.A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | 2026-12-31 |
| NCT05980949Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyOpen-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) | 2027-09-07 |
| NCT07682155Germans Trias i Pujol HospitalStudy of the Brain's Natural Cleaning System in Potential Organ Donors. | 2026-11-30 |
| NCT07639645University of ValenciaIntervention to Reduce Unwanted Loneliness in Family Caregivers of People With Alzheimer | 2026-12 |
Add all 20 to your calendar (.ics) → With an account.
Among the 279 studies in Alzheimer Disease with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The absence of social relationships negatively affects physical, psychological, and social health. In other words, it alters people's quality of life and makes active aging difficult. The investigators have designed a study to reduce unwanted loneliness and improve the living with process of family caregivers of people with Alzheimer disease through multiple interventions (music therapy, health education)
This project proposes a multimodal and interdisciplinary intervention aimed at alleviating or reducing unwanted loneliness and improving the living with process of family caregivers of individuals with Alzheimer's disease (AD). In doing so, it seeks to enhance their health and overall quality of life. The intervention will include activities such as health education, physical activity and music therapy.
The interdisciplinary team will also incorporate citizen participation, specifically through the involvement of an individual who has previously been a family caregiver of a person with AD. There is a growing body of evidence indicating that citizen participation in healthcare is highly advisable, as it is expected to improve the quality and relevance of outcomes.
This is a prospective, longitudinal, analytical, and experimental study.
The proposed study will involve different groups and the program will last for a total of 12 weeks. The program will include the following activities:
Physical exercise adapted to the physical conditions of each participant. Total of 12 sessions.
Health education workshops. A total of 12 workshops. These will include group training talks on the following topics: sleep hygiene, diet, and cognitive stimulation, Alzheimer disease, among others.
Music therapy workshops. Through listening to songs, singing, dancing, guided relaxation with music, and group instrumental performance, the enjoyment and expression of feelings will be encouraged. There will be 1 session per week. Total 12 sessions
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The multimodal interventions includes: 1. Behavioral: Health education for family caregivers of patients with Alzheimer disease with unwanted loneliness Twelve health education workshops will be carried out. These include group training talks on the following topics: sleep hygiene, diet, and cognitive stimulation, among others. 2. Behavioral: Music therapy for community-dwelling individuals with unwanted loneliness Description: Music therapy workshops will implemented. The enjoyment and expression of feelings will encouraged by listening to songs, singing, dancing, guided relaxation with music, and group instrumental performance. One session per week. Total 12 sessions 3. Behavioral: Physical exercise adapted to the physical conditions of each participant. Total of 12 sessions.
Behavioral: Multimodal intervention to Reduce Unwanted Loneliness in Family Caregivers of People With Alzheimer
This group will receive the ussual care in the day centers for familiar caregiver
The multimodal intervention will include these activities: 1. Health education workshops 2. Music therapy sessions 3. Physical exercise adapted to the physical conditions of each participant.
Score on the Jong Gierveld Lonelinss Scale
Loneliness Scale Social isolation will be measured with the Jong Gierveld Loneliness Scale. The final score is the total score for the 11 items, with the lowest possible score being 0 (no loneliness) and the highest being 11 (severe loneliness). Three categories have been proposed based on the score: a score of 0-2 points = no loneliness; a score of 3-8 points = moderate loneliness; and a score of 9-11 points = severe loneliness.
Time frame: From the beginning of the enrollement until the end of the intervention at 12 weeks
Living with chronic conditions from the family perspective
Living with LTCs scale from the perspective of the family caregiver (EC- PC- Fam). This is an instrument adapted from the original EC- PC.29-31 The adaptation process of the instrument and prior pilot study have been previously described in detail.23 The validated version has 31 items and 5 domains: (1) acceptance, (2) coping, (3) self- management, (4) integration and (5) adaptation. All the items follow a Likert scale of 5 points answer system, from never or none (0) to always and much (4), except for the items from the acceptance domain, which must be inverted to obtain results such as never or none (4) or always or much (0). The scores range from 0 to 155, with a higher score indicating more positive living with LTCs.
Time frame: From the enrollment to the end of the intervention at 12 weeks
Score in Goldberg Anxiety and Depression Scale.
The symptoms of anxiety and depression will be measured with the Goldberg Anxiety and Depression Scale. This is a questionnaire that discriminates between the diagnosis of anxiety and depression and measures their retrospective intensities. It consists of two subscales: one for anxiety and one for depression. Each subscale is composed of 9 dichotomous response items (YES or NO) to determine whether the subject has had any of the indicated symptoms in the last two weeks. The cut-off points are 4 or more items or affirmative responses for the anxiety scale and 2 or more for the depression scale. The higher the score, the greater the severity of the problem, with a maximum possible score of 9 points for each subscale.
Time frame: From enrollement until the end of the intervention ar 12 weeks
The score in the EuroQQL-5
The EuroQOL- 5 Dimensions 5- Level version (EQ- 5D- 5L) is an instrument designed to generically measure HRQOL, which can be used by both a healthy population and an individual with pathologies. The instrument developed by the EUROQOL group32 has been validated in many countries, including Spain.33 34 Different versions can be found, and in the present study, the EQ- 5D- 5L was selected due to the increase in the specificity of the responses as compared with the EQ- 5D- 3L. It is a self- administered instrument in which individuals assess their own health, first in a descriptive manner for each of the dimensions (mobility, personal care, everyday activities, pain/ discomfort and anxiety/depression), with five levels, from 0 to 5, and then with a more general Visual Analogical Scale. For the Spanish context, the psycho metric properties of the EQ- 5D- 5L scale were analysed in patients35 with the results indicating a reliability of 0.86.
Time frame: From enrollement until the end of the intervention at 12 weeks
Score in Zarit Test for caregiver burden
Zarit test: This scale is included to verify the external validity (divergent validity) of the EC- PC- Fam. This scale, originally named Caregiver Burden Interview, is designed to assess the burden of caregivers of indi viduals with dementia, from the general theory of the items39. It has 22 items that evaluate the negative repercussions on specific areas of daily life associated with caregiving: physical health, psychological health, social activities and economic resources. As opposed to the original, the version validated in Spain40 includes a 5- point Likert scale, for a total score that ranges from 22 to 110. In this study, different cut- off points were proposed: from 22 to 46, without burden; from 47 to 55, with burden and from 56 to 110, intense burden. The scale obtained an internal consistency of 0.91 and test-retest reliability of 0.96.
Time frame: From enrollement until the end of the intervention at 12 weeks
Plan to share: No
Start is estimated for Oct 2026; primary completion for Dec 2026, 2 months later.
Of 887 non-industry interventional studies with no phase under Alzheimer Disease, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 2 months is below that.
Counting every sponsor, half of 964 studies reached it within 29 months; a quarter within 15 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.